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Abstract
Nanoparticle (NP) drug loading is one of the key defining characteristics of a NP formulation.
However, the effect of NP drug loading on therapeutic efficacy and pharmacokinetics has not been
thoroughly evaluated. Herein, we characterized the efficacy, toxicity and pharmacokinetic
properties of NP docetaxel formulations that have differential drug loading but are otherwise
identical. Particle Replication in Non-wetting Templates (PRINT®), a soft-lithography fabrication
technique, was used to formulate NPs with identical size, shape and surface chemistry, but with
variable docetaxel loading. The lower weight loading (9%-NP) of docetaxel was found to have a
superior pharmacokinetic profile and enhanced efficacy in a murine cancer model when compared
to that of a higher docetaxel loading (20%-NP). The 9%-NP docetaxel increased plasma and tumor
docetaxel exposure and reduced liver, spleen and lung exposure when compared to that of 20%-
NP docetaxel.
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NP drug delivery has the potential to improve the effectiveness of small molecule
chemotherapeutics. Though design parameters such as particle geometry [1–5] and surface
chemistry [6] have been extensively studied to improve passive targeting, the effect of NP
drug loading on therapeutic efficacy and pharmacokinetics has not been evaluated. NP drug
loading is highly variable and often dependent upon the fabrication process. Polymeric
formulations prepared by nanoprecipitation typically only achieve 1–2% drug loading, but
NPs prepared by emulsion/solvent evaporation have reported drug loadings as high as 14%
[7,8]. Other commonly used nanocarriers that encapsulate chemotherapeutics such as
liposomes, microemulsions and micelles also only achieve ~10% drug loading [9–12].
Little is known about the the relationship between drug loading in NPs and the
pharmacokinetics and efficacy of small molecules in vivo. To fill this knowledge gap, we
aimed to compare particles with two different drug loadings. To accomplish this, we
prepared biodegradable NPs containing docetaxel using the soft-lithography template-based
fabrication approach known as PRINT®. The PRINT® technology is capable of fabricating
size and shape-specific particles with variable loadings of docetaxel [13]. In this report, the
pharmacokinetics and efficacy of two identically sized and shaped NPs at 9% or 20%
docetaxel loading were evaluated in vivo.
2. Materials and Methods
2.1 Materials
Poly(D,L-lactide-co-glycolide) (lactide:glycolide 85:15, 0.65 dL/g Inherent Viscosity at
30°C) and Poly(L-lactide) (0.5 dL/g Inherent Viscosity at 25°C) were purchased from
Sigma-Aldrich. Chloroform and solvents (acetonitrile and water) for high performance
liquid chromatography (HPLC) were purchased from Fisher Scientific. Docetaxel was
purchased from LC Laboratories. Taxotere® (free docetaxel) was purchased from the
University of North Carolina at Chapel Hill hospital pharmacy for research purposes.
Poly(ethylene terephthalate) (PET) sheets (6” width) were purchased from KRS plastics.
Fluorocur®, diameter (d) = 80 nm; height (h) = 320 nm; (80×320) prefabricated molds and
2,000 g/mol polyvinyl alcohol (PVOH) coated PET sheets were provided by Liquidia
Technologies.
2.2 Particle Fabrication and Characterization
Particles were fabricated with solutions of PLA, PLGA and docetaxel dissolved in
chloroform. The ratio of PLA:PLGA was 30:70. Two particle formulations at different
weight percents of docetaxel were prepared. The particle fabrication and characterization
follows previously published methods [13].
2.3 A549 human alveolar adenocarcinoma tumor xenografts
This study was done with an approved protocol with the University of North Carolina at
Chapel Hill’s Institutional Animal Care and Use Committee. All animals used were treated
humanely. A549 cells were acquired from ATCC. Female nude mice, aged 4–6 weeks and
~20 grams in body weight, were ordered from University of North Carolina at Chapel Hill’s
animal core. The mice were acclimated for 1 week prior to tumor cell injection. Cells
(5.0×106 cells in 200 µL 1xPBS) were injected subcutaneously into the right flank of each
mouse. Tumor volume was calculated using the formula: tumor volume (mm3) = (w2 × l)/2,
where w = width and l = length in mm of the tumor.
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For the orthotopic lung cancer model, A549-luciferase-c8 cells were harvested and
suspended in phosphate buffered saline and BD Matrigel Basement Membrane Matrix at a
ratio of 4:1. Cells (5.0×106 cells in 50 µL 1xPBS:Matrigel) were injected directly into the
left lung parenchyma [14].
2.4 Pharmacokinetic study
40 days after cells were inoculated subcutaneously when all mice had a median tumor
volume of 150 mm3, mice were pair matched according to tumor volume. All mice received
10 mg/kg docetaxel via a single tail vein injection. Formulations were diluted to 1 mg/mL of
docetaxel with normal saline and mice were dosed at 10 µL of solution per gram of body
weight. Mice (N=3 per time point per arm) were sacrificed at 0.083, 1, 6, 24, 72, and 168
hours after dosing. Blood (~1 mL) was collected via terminal cardiac puncture using K3-
EDTA as an anticoagulant under CO2 anesthesia and processed for plasma by centrifugation
(1,500 × g for 5 min). Plasma and tissues were placed in cryopreservation vials and
preserved by snap freezing using liquid nitrogen, and stored at −80°C until analysis. Tissues
were homogenized in water (1:3, tissue:water) prior to analysis [15].
2.5 Protein precipitation
Docetaxel and paclitaxel stock solutions (1 mg/mL) were stored in methanol at −20°C. The
standard curve concentrations of docetaxel in matrix were 1, 3, 5, 10, 30, 50, 100, 300, 500,
1000, 3000 and 5000 ng/mL and the quality control (QC) concentrations were 4, 40, 400,
and 4000 ng/mL. The matrix for the standard curve and QCs consisted of control mouse
plasma for all plasma samples, or control plasma mixed 1:1 with a control tissue
homogenate for the tissue being analyzed. A liver/plasma surrogate matrix was used for
tumor samples. All tumor and tissue samples were mixed 1:1 with control plasma prior to
analysis. Docetaxel was dissolved from the NP and extracted from 50 µL of sample by
protein precipitation with 200 µL acetonitrile/0.1% formic acid containing 20 ng/mL
paclitaxel internal standard. Samples were vortexed for 5 minutes and centrifuged at 3,000 ×
g for 10 minutes at 4°C. 170 µL supernatant was transferred to a clean 1.5 mL tube,
lyophilized under nitrogen and reconstituted in 60 µL of MeOH/0.1% formic acid. 50 µL of
sample was transferred to a silanized glass 96-well plate insert containing 50 µL ddH2O and
10 µL of sample injected for LC-MS/MS analysis.
2.6 LC-MS/MS
Docetaxel and paclitaxel (internal standard) were separated on a Waters XSelect CSH
Phenyl-Hexyl column (2.1×50 mm, 130 Å pore size, 5 µm particle size) using a gradient
mobile phase consisting of 0.1% formic acid in water (mobile phase A) and 0.1% formic
acid and 10% isopropanol in acetonitrile (mobile phase B) on a Shimadzu LC-20AD liquid
chromatography system. The flow rate was 0.33 mL/min and the total run time was 6
minutes. The compounds were measured using a Thermo TSQ Ultra triple quadrupole mass
spectrometer equipped with a heated electrospray ionization source in the positive ion mode.
The discharge current was held at 3.7 kV and the vaporizer temperature at 225°C. Docetaxel
and paclitaxel were detected by selected-reaction monitoring (SRM) using the transitions
808 −> 527 and 854 −> 286, respectively. Calibration curves were fit using linear regression
with 1/X2 weighting in Xcalibur® v. 2.0 (Thermo Fisher Scientific, Waltham, MA).
2.7 Maximum Tolerated Dose Determination
The maximum tolerated doses (MTD) of free docetaxel and the docetaxel NPs were
determined for a weekly × 6 schedule in female nude mice. At time of the first dose, mice
were 6 weeks in age. Mice were monitored for body weight loss and overall health. Mice
were sacrificed if body weight loss exceeded 20% or if they exhibited excessive signs of
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toxicity. The MTD was selected as the dose that did not cause excessive toxicity that
required a mouse to be sacrificed or body weight loss greater than 10%.
2.8 Tumor Growth Inhibition Studies
16 days after cell inoculation to the lung, mice were randomized into four groups (N=8 mice
per group for mice receiving free docetaxel, 9%-NP, or 20%-NP and N=6 mice per group
for mice receiving saline). Mice were dosed via tail vein at 10 µL per gram body weight.
Mice either received saline, 10 mg/kg docetaxel for free docetaxel, or 15 mg/kg docetaxel
for mice receiving 9%-NP and 20%-NP. Mice were sacrificed when they had excessive
body weight loss or excessive toxicity. Mice were imaged once a week using an IVIS
Lumina Imager. Prior to imaging, mice were injected 10 µL per gram body weight with a 15
mg/mL luciferase solution. Mice were anesthetized with isoflurane prior to imaging.
2.9 Hematological Tests
50 µL of blood was collected into EDTA-coated tubes by submandibular bleeding the day of
the first injection, 4 days after the 1st injection and 4 days after the 6th injection. Blood was
analyzed for complete blood counts with differential using Heska’s blood counter.
2.10 Statistical and Pharmacokinetic Analysis
GraphPad Prism was used to perform statistical tests. Student’s t-test was utilized when only
two groups were compared. One way analysis of variance (ANOVA) followed by a
modified t-test for multiple comparisons was used when more than 2 groups were compared.
Survival data was analyzed by Log-Rank test. Pharmacokinetic data was analyzed by
noncompartmental methods using WinNonlin Professional Edition version 5.2.1 (Pharsight
Corp, Cary, NC). The area under the concentration versus time curve from 0 to t (AUC0-t)
was calculated using the linear up/log down rule. Volume of distribution (Vd) and clearance
(CL) were calculated using standard equations. The maximum concentration (Cmax) and




To achieve different loadings, PLA/PLGA particles were fabricated with different amounts
of docetaxel. Despite having different drug loadings of docetaxel, all other particle
characteristics were identical as shown in Table 1. As measured by dynamic light scattering
(DLS), both sets of 80×320 NPs were 216 nm in hydrodynamic diameter with polydispersity
indices (PDI) of less than 0.1. The total percent drug released after 24 hours was similar for
both NPs (Figure 1), but the 20%-NP had slightly faster burst release within the first 6 hours
compared to the 9%-NP.
3.2 Pharmacokinetics
The pharmacokinetic parameters and profiles of the 9%-NP and 20%-NP are shown in Table
2 and Figure 1. The sum total (encapsulated and released) docetaxel was measured and is
reported.
Docetaxel plasma exposure as measured by AUC of the concentration – time curve was
1.15-fold higher for mice receiving 9%-NPs compared to 20%-NPs. The Vd and CL of
docetaxel was lower for the 9%-NP group. The Cmax observed in both NP groups were not
statistically significant and T1/2 were similar. Docetaxel was not detectable at 168 hours post
injection for both NPs.
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Large differences in tissue docetaxel accumulation were observed between both NP groups.
Mice receiving 9%-NP had 1.39-fold higher tumor docetaxel exposure than mice receiving
20%-NP. Maximum tumor docetaxel concentrations were not statistically significant
between the two NP groups, but the Cmax was observed at different times. For the 20%-NP
group, the Cmax was observed immediately after injection at 5 minutes, where as the Cmax of
the 9%-NP group was observed at 24 hours post injection.
Liver exposure of the 20%-NP group was ~1.40-fold higher than the 9%-NP group, but the
observed Cmax of both groups were not statistically significant. At 6 and 72 hours post
injection, the docetaxel concentration of the 20%-NP group was statistically higher than the
9%-NP group: P=0.02 at 6 hours (12,468 ± 1,512 versus 8,025 ± 2,214) and P=0.05 at 72
hours (10,464 ± 2,828 versus 5,765 ± 525). Spleen exposure of the 20%-NP group was
~1.31-fold higher than the 9%-NP group. Spleen docetaxel concentration was statistically
higher for the 20%-NP group at 1 hour post injection (P=0.03, 73,061 ± 10,855 versus
31,117 ± 19,382). Lung exposure of the 20%-NP group was ~1.56-fold higher than the 9%-
NP group.
3.3 Maximum Tolerated Dose
The maximum tolerated dose of free docetaxel and the 20%-NP was determined in female
non tumor bearing nude mice following a weekly dosing schedule for 6 weeks. The MTD of
free docetaxel was expected to be 13–20 mg/kg [16,17]. Poly(L-lactide) NPs containing
taxanes have been shown to have a higher MTD than the free taxane formulation [18]. Thus,
20 mg/kg was selected as the starting dose for the free docetaxel group and 30 mg/kg was
selected as the starting dose for the docetaxel NP group.
The MTD of free docetaxel in female non tumor bearing mice was found to be 20 mg/kg
weekly for 6 weeks. 2 mice were sacrificed within the 27 mg/kg arm and 1 mouse was
sacrificed in the 35 mg/kg arm for excessive toxicity. Additionally, mice in both the 27 mg/
kg and 35 mg/kg free docetaxel arms had body weight loss that surpassed 10%. The MTD of
the docetaxel NPs was found to be 30 mg/kg weekly for 6 weeks. At 37.5 mg/kg, 2 mice
were sacrificed after the 6th dose and at 45 mg/kg, all mice were sacrificed after the 6th dose.
Also, the mean body weight loss of mice receiving 37.5 mg/kg and 45 mg/kg exceeded 10%.
The mean body weights and survival are shown in Figure 2 and Table 3, respectively.
3.4 White blood cell counts
White blood cell counts (WBC) were measured one week before the 1st injection and 4 days
after the 1st and 6th injection of free docetaxel or docetaxel NPs and are reported in Table 4.
WBC counts of all groups were not statistically significant 1 week before the 1st dose as
measured by one-way ANOVA. Mice receiving 9%-NP or 20%-NP did not have statistically
significant differences in their WBC 4 days after the 1st and 6th dose.
3.5 Tumor Growth Inhibition
Efficacy was evaluated in an orthotopic tumor model of non small cell lung cancer. Because
MTDs of the docetaxel formulations were determined in non tumor bearing mice, the MTDs
may be lower in mice with orthotopic lung xenografts. To avoid toxicity attributed to
docetaxel, mice received doses that were half of the MTD in non-tumor bearing mice.
Survival analysis by Kaplan-Meier estimate demonstrated that 9%-NP was the superior
treatment (P=0.03 compared to free docetaxel). Mice that received 9%-NPs or 20%-NPs had
minimal or no tumor growth even 150 days post cell implantation (Figure 3). 6/6 mice in the
saline group and 6/8 mice in the free docetaxel treatment groups had tumor growth that
required mice to be sacrificed.
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We studied drug loading as a parameter that affects the therapeutic efficacy,
pharmacokinetics and toxicity of docetaxel. Most NP fabrication techniques are limited to
drug loadings of ~10%. PRINT® has previously demonstrated the ability to make NPs with
variable drug loadings. Therefore, we prepared one NP formulation to match the loading of
a taxane NP that is currently in clinical development [7] and for comparison, a second NP
formulation was prepared that targeted to double the loading to 20%.
There are multiple benefits of preparing NP formulations with higher drug loading. Higher
drug loading is preferable because less non active excipients are used to produce the same
quantity of active pharmaceutical ingredient (API) in the NP formulation. At a higher drug
loading, a lower number of particles need to be manufactured to deliver an equivalent dose
of API. Reducing the number of NPs that need to be manufactured can reduce
manufacturing and processing time, raw material usage, and energy needs as many NP
manufacturing processes require input of mechanical energy.
From a manufacturing viewpoint, achieving the highest drug loading possible is desired, but
we have demonstrated that there are benefits in using NPs with lower drug loading. Mice
receiving the 9%-NPs had more favorable pharmacokinetic profile compared to mice
receiving 20%-NP. Less liver and spleen accumulation as measured by AUC was observed
in mice receiving 9%-NPs compared to the 20%-NPs. Though all mice in the NP arms
received 15 mg/kg of docetaxel, the total dose of particles received in the 9%-NP group was
~109 mg/kg compared to only 50 mg/kg in the 20%-NP group. The higher particle dose
associated with the 9%-NP formulation may have saturated the mononuclear phagocyte
system (MPS) of the liver and spleen. Reduced docetaxel accumulation in the liver and
spleen of mice receiving 9%-NP may account for the increased plasma and tumor docetaxel
exposure relative to the 20%-NP group. Tumor docetaxel concentration increased during the
first 24 hours post injection for the 9%-NP group where as the 20%-NP group reached
docetaxel Cmax immediately after injection.
Multiple preclinical studies have evaluated the effect of concurrently or pre-administering
NPs on the pharmacokinetics of a second dose of NPs [19–24]. These studies demonstrated
that NP clearance could be limited by the saturation of the mononuclear phagocyte system
(MPS), most notably in the liver by NPs. Additionally, differences in MPS saturation were
observed between liposomes and polymeric particles of different compositions and surface
chemistries [21,22,24]. Similarly, increasing the number of particles injected may saturate
the MPS. Future studies are planned to investigate this phenomenon in more depth. Assays
to identify the drug distribution in the cells of the MPS after administration of docetaxel NPs
to mice are currently being developed.
5. Conclusion
In this report, the dependence of small molecule pharmacokinetics on drug loading in a NP
was demonstrated in vivo. Mice that received a 9%-NP formulation compared to a 20%-NP
formulation had ~24–36% less docetaxel exposure in organs of the MPS, and as a result, had
increased plasma and tumor docetaxel exposure of ~16% and 39%, respectively. Saturation
of the MPS due to an increased particle dose may be responsible for the observed
differences in docetaxel exposure. Particle dose and drug loading are critical formulation
parameters used to help maximize the pharmacokinetics of small molecules. With
maximized docetaxel plasma and tumor exposure, an increase in therapeutic efficacy of the
9%-NP was observed in an orthotopic xenograft mouse model. As variations in drug loading
may alter in vivo performance, these findings highlight drug loading as an important
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consideration in the manufacturing of NPs. Achieving consistency in the particle
manufacturing process may ensure that particle batches not only have bioequivalence as
measured by in vitro assays, but also maintain bioequivalence in vivo.
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Pharmacokinetic profiles of (A) Plasma, (B) Tumor, (C) Liver, (D) Spleen and (E) Lung. (F)
In vitro release kinetics of 9%-NP (●) and 20%-NP (■). Each replicate is shown and the
lines are connected by the mean of three replicates.
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Mean body weight of mice in MTD study. Dose 1 was on Day 0.
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Tumor growth rates and Kaplan-Meier curve of mice with A549 orthotopic lung xenografts.
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Table 1
Particle Characteristics of 9%-NP and 20%-NP.
Formulation Size (nm) PDI Zeta Potential (mV) Weight percent docetaxel
20%-NP 216 ± 2 0.07 ± 0.01 −3.36 ± 0.16 20.1 ± 1.5
9%-NP 216 ± 1 0.09 ± 0.03 −3.11 ± 0.28 9.2 ± 1.6
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Table 2
Docetaxel pharmacokinetic parameters of 9%-NP and 20%-NP
Specimen Parameter Formulation
9%-NP 20%-NP
Plasma AUC (ng/mL h) 95,692 (0–72 h) 82,743 (0–72 h)
Cmax (ng/mL) 19,583 ± 7,997 26,753 ± 5,603
CL (mL/h/kg) 105 121
Vd (mL/kg) 943 1278
T1/2 (h) 6.6 7.4
Tumor AUC (ng/mL h) 99,586 (0–168 h) 71,848 (0–168 h)
Cmax (ng/mL) 1,199 ± 1,115 1038 ± 366
Liver AUC (ng/mL h) 1,080,179 (0–168 h) 1,513,225 (0–168 h)
Cmax (ng/mL) 16,359 ± 11,681 19,274 ± 10,838
Spleen AUC (ng/mL h) 5,282,385 (0–168 h) 6,934,196 (0–168 h)
Cmax (ng/mL) 44,294 ± 26,239 73,061 ± 10,855
Lung AUC (ng/mL h) 165,962 (0–168 h) 258,766 (0–168 h)
Cmax (ng/mL) 17,218 ± 6,347 20,200 ± 2,861
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Table 3
Survival at each dose level for MTD study.
Formulation
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Table 4








1 week before 1st dose 3.8 ± 1.1 4.7 ± 2.0 3.6 ± 0.8 3.7 ± 0.8
4 days after 1st dose 3.1 ± 1.1 2.2 ± 0.5 1.4 ± 0.8 1.6 ± 0.6
4 days after 6th dose 2.3 ± 0.6 1.9 ± 0.6 1.1 ± 0.3 1.0 ± 0.4
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